Summit Therapeutics (SMMT) Set to Release Quarterly Earnings on Monday

Summit Therapeutics (NASDAQ:SMMT) will likely be issuing its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect Summit Therapeutics to announce earnings of ($0.2817) per share and revenue of $0.11 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 9, 2026 at 7:00 AM ET.

Summit Therapeutics Price Performance

SMMT traded down $0.06 during trading on Wednesday, reaching $15.74. 811,298 shares of the stock traded hands, compared to its average volume of 4,608,931. The stock has a market cap of $12.59 billion, a price-to-earnings ratio of -13.96 and a beta of -1.49. Summit Therapeutics has a fifty-two week low of $12.07 and a fifty-two week high of $29.23. The stock’s 50-day simple moving average is $16.15 and its two-hundred day simple moving average is $16.16.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on SMMT shares. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Summit Therapeutics in a research note on Monday, October 5th. UBS Group reissued a “neutral” rating on shares of Summit Therapeutics in a research note on Wednesday, September 23rd. Leerink Partners upgraded Summit Therapeutics from an “underperform” rating to a “market perform” rating and increased their price objective for the stock from $12.00 to $13.00 in a report on Wednesday, August 12th. Wall Street Zen raised shares of Summit Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 5th. Finally, Barclays raised their price objective on shares of Summit Therapeutics from $18.00 to $20.00 and gave the company an “equal weight” rating in a research report on Thursday, October 1st. One equities research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $28.61.

About Summit Therapeutics

Summit Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative medicines for the treatment of cancer. The company’s primary focus is oncology, with an emphasis on therapies designed to improve outcomes for patients with serious diseases.

Summit’s lead product candidate is ivonescimab, a bispecific antibody that is designed to combine immune checkpoint inhibition against PD-1 with anti-angiogenic activity targeting VEGF. The company is advancing ivonescimab in clinical studies for non-small cell lung cancer and is evaluating the therapy in combination with other cancer treatments and across additional treatment settings.

Summit holds exclusive rights to develop and commercialize ivonescimab in markets outside China through a licensing and collaboration agreement with Akeso, a China-based biopharmaceutical company.